Physician profile
Swarup Kumar
NPI 1629451497
$11,545.78
in general payments reported to CMS, 2019-2025
11 companies · $9,427 in 2025
The $9,427 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.15 · 2023: $964 · 2024: $1,110 · 2025: $9,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,341 · Travel and Lodging: $1,771 · Food and Beverage: $1,372 · Education: $17.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,341.00 |
| Travel and Lodging | $1,771.35 |
| Food and Beverage | $1,372.12 |
| Education | $17.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $6,049.04 | 2025 | |
| Janssen Biotech, INC. | $2,019.54 | 2025 | Talvey, Tecvayli, Darzalex |
| Janssen Scientific Affairs, LLC | $1,394.91 | 2024-2025 | Darzalex, Tecvayli, Carvykti |
| Adaptive Biotechnologies Corporation | $964.13 | 2023 | Clonoseq |
| Janssen Research & Development, LLC | $928.74 | 2024 | Tecvayli |
| Pfizer INC. | $123.96 | 2024-2025 | |
| Amgen INC. | $27.36 | 2022 | |
| Kite Pharma, INC. | $21.31 | 2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $16.79 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swarup Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.